Liftstream is an executive search recruitment company in the life sciences sector
Roche Snags Phase III Agromegaly Drug from Chiasma
Roche have announced they have acquired the rights to a phase III oral Agromegaly drug Octreolin from, Israeli biotech, Chiasma. Agromegaly is a rare progressive disease caused by the over production of growth hormone resulting in severe disfigurement. Agromegaly is estimated to occur in approximately 6 in every 100,000 people.
Posted in M&A Finance and Funding
Tagged Abingworth, Agromegaly, Chiasma, EMA, FDA, MAA, MPM Capital, Octreolin, Orphan Drug, Phase III, Roche, Series D
Leave a comment
Sangart awaits key clinical data in 2013
Authored by James Sheppard
NPS Pharmaceuticals gets ready to launch gastro orphan drug
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged commercial, endocrinology, europe, FDA, gastroenterology, Gattex, hormone, Market Access, marketing, Natpara, NPS Pharmaceuticals, Nycomed, Orphan Drug, patients, pricing and reimbursement, Revestive, short bowel syndrome, Takeda, teduglutide, ultra-rare diseases, USA
Leave a comment
Bluebird bio sings to tune of $9.3m as gene therapy shows promise
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged Alnylan Pharmaceuticals, ARCH Ventures, beta-thalassemia/sickle cell anemia, Biogen IDEC, Bluebird bio, CCALD, celgene, childhood cerebral adrenoleukodystrophy, Deerfield partners, Genzyme, LentGlobin, Mark Levin, Nick Leschly, Orphan Drug, rare diseases, Shire, Third Rock Ventures, venture capital
Leave a comment